Tags

Type your tag names separated by a space and hit enter

Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.
Am J Cardiol. 2014 Jul 01; 114(1):151-9.AJ

Abstract

The 2013 American College of Cardiology Foundation/American Heart Association guidelines recommend combined isosorbide dinitrate (ISDN) and hydralazine to reduce mortality and morbidity for African-Americans with symptomatic heart failure (HF) and reduced ejection fraction, currently receiving optimal medical therapy (class I, level A). Nitrates can alleviate HF symptoms, but continuous use is limited by tolerance. Hydralazine may mitigate nitrate tolerance, and the ISDN-hydralazine combination in the Vasodilators in Heart Failure Trial (V-HeFT) I improved survival and exercise tolerance in men with dilated cardiomyopathy or HF with reduced ejection fraction, most notably in self-identified black participants. In the subsequent V-HeFT II, survival was greater with enalapril than with ISDN-hydralazine in the overall cohort, but mortality rate was similar in the enalapril and ISDN-hydralazine groups in the self-identified black patients. Consequently, in the African-American Heart Failure Trial (A-HeFT) in self-identified black patients with symptomatic HF, adding a fixed-dose combination ISDN-hydralazine to modern guideline-based care improved outcomes versus placebo, including all-cause mortality, and led to early trial termination. Hypertension underlies HF, especially in African-Americans; the A-HeFT and its substudies demonstrated not only improvements in echocardiographic parameters, morbidity, and mortality but also a decrease in hospitalizations, potentially affecting burgeoning HF health-care costs. Genetic characteristics may, therefore, determine response to ISDN-hydralazine, and the Genetic Risk Assessment in Heart Failure substudy demonstrated important hypothesis-generating pharmacogenetic data.

Authors+Show Affiliations

Tulane University School of Medicine, New Orleans, Louisiana. Electronic address: kferdina@tulane.edu.University of Southern California Keck School of Medicine, Los Angeles, California.Columbia University College of Physicians and Surgeons, New York, New York.Morehouse School of Medicine, Atlanta, Georgia.Montefiore Einstein Center for Heart and Vascular Care, Bronx, New York.Minneapolis VA Medical Center, Minneapolis, Minnesota.Temple University Health System, Philadelphia, Pennsylvania.University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.East Georgia Regional Medical Center, Statesboro, Georgia.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24846808

Citation

Ferdinand, Keith Copelin, et al. "Use of Isosorbide Dinitrate and Hydralazine in African-Americans With Heart Failure 9 Years After the African-American Heart Failure Trial." The American Journal of Cardiology, vol. 114, no. 1, 2014, pp. 151-9.
Ferdinand KC, Elkayam U, Mancini D, et al. Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial. Am J Cardiol. 2014;114(1):151-9.
Ferdinand, K. C., Elkayam, U., Mancini, D., Ofili, E., Piña, I., Anand, I., Feldman, A. M., McNamara, D., & Leggett, C. (2014). Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial. The American Journal of Cardiology, 114(1), 151-9. https://doi.org/10.1016/j.amjcard.2014.04.018
Ferdinand KC, et al. Use of Isosorbide Dinitrate and Hydralazine in African-Americans With Heart Failure 9 Years After the African-American Heart Failure Trial. Am J Cardiol. 2014 Jul 1;114(1):151-9. PubMed PMID: 24846808.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial. AU - Ferdinand,Keith Copelin, AU - Elkayam,Uri, AU - Mancini,Donna, AU - Ofili,Elizabeth, AU - Piña,Ileana, AU - Anand,Inder, AU - Feldman,Arthur Michael, AU - McNamara,Dennis, AU - Leggett,Christopher, Y1 - 2014/04/18/ PY - 2013/12/18/received PY - 2014/04/03/revised PY - 2014/04/03/accepted PY - 2014/5/22/entrez PY - 2014/5/23/pubmed PY - 2014/8/1/medline SP - 151 EP - 9 JF - The American journal of cardiology JO - Am J Cardiol VL - 114 IS - 1 N2 - The 2013 American College of Cardiology Foundation/American Heart Association guidelines recommend combined isosorbide dinitrate (ISDN) and hydralazine to reduce mortality and morbidity for African-Americans with symptomatic heart failure (HF) and reduced ejection fraction, currently receiving optimal medical therapy (class I, level A). Nitrates can alleviate HF symptoms, but continuous use is limited by tolerance. Hydralazine may mitigate nitrate tolerance, and the ISDN-hydralazine combination in the Vasodilators in Heart Failure Trial (V-HeFT) I improved survival and exercise tolerance in men with dilated cardiomyopathy or HF with reduced ejection fraction, most notably in self-identified black participants. In the subsequent V-HeFT II, survival was greater with enalapril than with ISDN-hydralazine in the overall cohort, but mortality rate was similar in the enalapril and ISDN-hydralazine groups in the self-identified black patients. Consequently, in the African-American Heart Failure Trial (A-HeFT) in self-identified black patients with symptomatic HF, adding a fixed-dose combination ISDN-hydralazine to modern guideline-based care improved outcomes versus placebo, including all-cause mortality, and led to early trial termination. Hypertension underlies HF, especially in African-Americans; the A-HeFT and its substudies demonstrated not only improvements in echocardiographic parameters, morbidity, and mortality but also a decrease in hospitalizations, potentially affecting burgeoning HF health-care costs. Genetic characteristics may, therefore, determine response to ISDN-hydralazine, and the Genetic Risk Assessment in Heart Failure substudy demonstrated important hypothesis-generating pharmacogenetic data. SN - 1879-1913 UR - https://www.unboundmedicine.com/medline/citation/24846808/Use_of_isosorbide_dinitrate_and_hydralazine_in_African_Americans_with_heart_failure_9_years_after_the_African_American_Heart_Failure_Trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(14)00975-8 DB - PRIME DP - Unbound Medicine ER -